UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2004
|
Nektar Therapeutics |
||||
|
(Exact Name of Registrant as Specified in Charter) |
||||
|
|
||||
|
Delaware |
||||
|
(State or Other Jurisdiction of Incorporation) |
||||
|
|
||||
|
000-23556 |
|
94-3134940 |
|
|
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
150 Industrial Road |
||||
|
San Carlos, CA 94070 |
||||
|
(Address of Principal Executive Offices and Zip Code) |
||||
|
|
||||
|
Registrant’s telephone number, including area code: (650) 631-3100 |
||||
Item 5. Other Events and Regulation FD Disclosure.
On March 30, 2004, Nektar Therapeutics issued a press release entitled “Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release, dated March 30, 2004, entitled “Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010” |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
NEKTAR THERAPEUTICS |
|
|
|
|
|
|
|
|
|
|
Dated: March 30, 2004 |
By: |
/s/ Ajit S. Gill |
|
|
|
Ajit S. Gill |
|
|
|
President, Chief Executive Officer and |
3
Exhibit Index
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release, dated March 30, 2004, entitled “Nektar Therapeutics Announces Completion of Redemption of 3% Convertible Subordinated Notes due June 2010” |
4